Details for Patent: 6,811,794

Which drugs does patent 6,811,794 protect, and when does it expire?

Patent 6,811,794 protects INTUNIV and is included in one NDA.

Protection for INTUNIV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,811,794

Title:	Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
Abstract:	A pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5. Such compositions have minimized pH-dependent dissolution profiles or pH-independent dissolution profiles.
Inventor(s):	Burnside; Beth A. (Bethesda, MD), Chang; Rong-Kun (Rockville, MD), Guo; Xiaodi (New City, NY)
Assignee:	Shire Laboratories, Inc. (Rockville, MD)
Application Number:	10/027,349
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,811,794
Patent Claim Types: see list of patent claims	Composition; Compound; Use; Dosage form;

Drugs Protected by US Patent 6,811,794

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	INTUNIV	guanfacine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022037-001	Sep 2, 2009	AB	RX	Yes	No					Y
Takeda Pharms Usa	INTUNIV	guanfacine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022037-002	Sep 2, 2009	AB	RX	Yes	No					Y
Takeda Pharms Usa	INTUNIV	guanfacine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022037-003	Sep 2, 2009	AB	RX	Yes	No					Y